Don't forget to nominate 2019's fiercest women in life sciences

Three people looking at a display of black and white photos depecting a diverse group of people
Your nominees may be industry professionals, academics, venture capitalists—any woman who's making a mark on the life sciences industry. (Gerd Altmann)

If you’ve been sitting on your nominations for this year’s Fiercest Women in Life Sciences, don’t wait too long! Now is the perfect time to submit them as nominations will close in two weeks.

To recap, we’re looking for women in biotech, pharma and medtech who, in spite of challenges both unique to the industry and to being female, stand out as leaders, innovators and mentors. They can be industry professionals, academics, venture capitalists—you name it.

We are often asked if we have a list of criteria for consideration. We don’t. If a particular woman is making a mark on the life sciences industry, we want to hear about her.

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

For a taste of what we’re looking for, check out last year's feature here and 2017’s here. Please submit your nominations using the form below. It will be open until 11:59 p.m. EDT on Monday, Aug. 19. 





Suggested Articles

Sanofi's Sarclisa is coming full-force at Johnson & Johnson blockbuster Darzalex in the multiple myeloma field—now backed by new data.

The antidepressant Zoloft and its generics are in short supply as the COVID-19 pandemic has caused higher demand and manufacturing interruptions.

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.